A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects

BACKGROUND: In type 2 diabetes mellitus, fixed-dose combination (FDC) can provide the complementary benefits of correction of multiple pathophysiologic defects such as dysfunctions in glycemic or metabolic control while improving compliance compared with separate tablets taken together. The objectiv...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Drug Des Devel Ther
Autores principales: Park, Sang-In, Lee, Howard, Oh, Jaeseong, Lim, Kyoung Soo, Jang, In-Jin, Kim, Jeong-Ae, Jung, Jong Hyuk, Yu, Kyung-Sang
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4324327/
https://ncbi.nlm.nih.gov/pubmed/25678778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S75980
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares